Menu Search
Equities

STERIS plc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0XI8:LSE

STERIS plc

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta1.0576
Data delayed at least 20 minutes.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.

  • Revenue in USD (TTM)5.83bn
  • Net income in USD708.66m
  • Incorporated2016
  • Employees17.79k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		STE:NYQ since
announced		Transaction
value
Medik Hospital Design GmbHDeal completed01 Dec 202501 Dec 2025Deal completed-5.30%--
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.